JP2019537599A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537599A5
JP2019537599A5 JP2019523739A JP2019523739A JP2019537599A5 JP 2019537599 A5 JP2019537599 A5 JP 2019537599A5 JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019537599 A5 JP2019537599 A5 JP 2019537599A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523739A
Other languages
English (en)
Japanese (ja)
Other versions
JP7097880B2 (ja
JP2019537599A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/059234 external-priority patent/WO2018085247A1/en
Publication of JP2019537599A publication Critical patent/JP2019537599A/ja
Publication of JP2019537599A5 publication Critical patent/JP2019537599A5/ja
Application granted granted Critical
Publication of JP7097880B2 publication Critical patent/JP7097880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523739A 2016-11-01 2017-10-31 Malt1分解のための化合物 Active JP7097880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416066P 2016-11-01 2016-11-01
US62/416,066 2016-11-01
PCT/US2017/059234 WO2018085247A1 (en) 2016-11-01 2017-10-31 Compounds for malt1 degradation

Publications (3)

Publication Number Publication Date
JP2019537599A JP2019537599A (ja) 2019-12-26
JP2019537599A5 true JP2019537599A5 (https=) 2020-12-10
JP7097880B2 JP7097880B2 (ja) 2022-07-08

Family

ID=62077048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523739A Active JP7097880B2 (ja) 2016-11-01 2017-10-31 Malt1分解のための化合物

Country Status (4)

Country Link
US (1) US10689366B2 (https=)
EP (1) EP3535254A4 (https=)
JP (1) JP7097880B2 (https=)
WO (1) WO2018085247A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2017081641A1 (en) * 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
MX2020006808A (es) 2017-12-28 2020-12-11 Massachusetts Gen Hospital Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
JP2021519337A (ja) 2018-03-26 2021-08-10 シー4 セラピューティクス, インコーポレイテッド Ikarosの分解のためのセレブロン結合剤
DK3904350T3 (da) 2018-04-12 2023-11-13 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamidderivater og de tilsvarende pyridincarboxamidderivater som pesticider
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
CN118344338A (zh) 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
MX2020011275A (es) 2018-04-25 2020-11-13 Bayer Ag Novedosos compuestos de heteroaril-triazol y hetroaril[-]tetrazol como plaguicidas.
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019242625A1 (zh) * 2018-06-20 2019-12-26 上海科技大学 制备来那度胺衍生物的方法
WO2020111087A1 (ja) * 2018-11-28 2020-06-04 武田薬品工業株式会社 複素環化合物
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
US20220274947A1 (en) 2019-07-23 2022-09-01 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
TW202128664A (zh) 2019-10-09 2021-08-01 德商拜耳廠股份有限公司 作為除害劑之新穎雜芳基三唑化合物
US20240383886A1 (en) * 2019-12-20 2024-11-21 Calico Life Sciences Llc Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
EP4138921A1 (en) * 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
JP7672402B2 (ja) 2020-05-27 2025-05-07 武田薬品工業株式会社 複素環化合物の製造方法
JP2023530937A (ja) * 2020-06-17 2023-07-20 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド E3-リガーゼ系の共動員を介した標的化された異常なα-シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
US20230414629A1 (en) * 2020-11-12 2023-12-28 Monopteros Therapeutics, Inc. Materials and methods of treating cancer
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
WO2022164830A1 (en) * 2021-01-29 2022-08-04 Eurofins Discoverx Corporation Molecular glue screening assays and methods for practicing same
WO2023125877A1 (zh) 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
IL314337A (en) * 2022-01-18 2024-09-01 Aurigene Oncology Ltd Substituted bicyclic heterocycles as malt-1 inhibitors
WO2023143249A1 (zh) * 2022-01-28 2023-08-03 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
EP4473966A4 (en) 2022-02-02 2026-01-21 Ono Pharmaceutical Co CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
CA3244869A1 (en) * 2022-02-25 2023-08-31 Tegid Therapeutics, Inc. PROTACS DE MALT1
JP2025523393A (ja) 2022-06-06 2025-07-23 シーフォー セラピューティクス, インコーポレイテッド 二環式置換グルタルイミドセレブロンバインダー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806274B1 (en) * 1999-07-07 2004-10-19 Astrazeneca Uk Limited Quinazoline derivatives
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
WO2009060835A1 (ja) * 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
WO2012071414A2 (en) * 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
US20150201001A1 (en) * 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
ES2738695T3 (es) 2014-05-28 2020-01-24 Novartis Ag Nuevos Derivados de Pirazolo Pirimidina y su uso como inhibidores de MALT1
WO2015187827A1 (en) * 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US10806737B2 (en) * 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides

Similar Documents

Publication Publication Date Title
JP2019537599A5 (https=)
JP2016509047A5 (https=)
JP2013512903A5 (https=)
JP2013500314A5 (https=)
JP2014508804A5 (https=)
JP2019510832A5 (https=)
JP2018522866A5 (https=)
JP2007504235A5 (https=)
JP2015532295A5 (https=)
JP2019524883A5 (https=)
JP2013510123A5 (https=)
JP2014510774A5 (https=)
RU2018137389A (ru) Гетероциклические амиды, полезные в качестве модуляторов
JP2009515980A5 (https=)
JP2010501584A5 (https=)
JP2018516238A5 (https=)
JP2018519245A5 (https=)
JP2008512490A5 (https=)
KR20170081228A (ko) 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
JP2017528498A5 (https=)
JP2009536620A5 (https=)
JP2015506348A5 (https=)
JP2009531403A5 (https=)
JP2010510237A5 (https=)
JP2016506962A5 (https=)